<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783614</url>
  </required_header>
  <id_info>
    <org_study_id>PCC-002</org_study_id>
    <nct_id>NCT00783614</nct_id>
  </id_info>
  <brief_title>Aspirin and Antiretroviral Therapy in HIV Infected Patients</brief_title>
  <official_title>The Effect of Aspirin and Antiretroviral Therapy on Cardiovascular Risk in HIV Infected Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minneapolis Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of HIV treatment (antiretroviral therapy)
      and aspirin use on risk for cardiovascular disease among HIV infected persons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is now a major health concern among persons with HIV infection. Our
      general hypothesis is that HIV-mediated inflammation and injury to vascular surfaces
      up-regulates thrombotic pathways and leads to damage of blood vessels that is promotes
      development of cardiovascular disease. HIV drug treatment (antiretroviral therapy; ART) may
      reduce inflammation and vessel injury via suppression of HIV replication, but also includes
      side effects or toxicity that may increase risk for cardiovascular disease in and of itself.
      In this context, additional anti-inflammatory and anti-thrombotic medications are needed.
      Acetylsalicylic acid (aspirin) is an excellent candidate and is commonly used for secondary
      prevention of cardiovascular events in the general population, but few studies have examined
      it's use in persons with HIV infection. The goal of this study is to generate pilot data
      regarding changes in measures of cardiovascular risk, as determined by reductions in
      inflammatory and thrombotic blood markers and a decrease in blood vessel injury (blood
      markers) and dysfunction (assessment of arterial elasticity), that occur after starting ART
      and aspirin among persons with HIV infection.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Side Effects (Self-report) Number of Participants With Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>At each visit participants were asked if they were experience side effects to study medications. They were also asked if any new events or symptoms occurred since the last visit, even if they did not suspect it was related to the study medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Markers of Inflammation, Endothelial Injury, and Thrombosis</measure>
    <time_frame>changes from baseline to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Start antiretroviral therapy (ART) immediately and initiate placebo pill daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 325mg</intervention_name>
    <description>Patients randomized to Aspirin 325mg po daily versus placebo pill daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral therapy (ART)</intervention_name>
    <description>Patients randomized to start ART immediately or defer use for 1 month</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-infected (by positive HIV Ab or detectable HIV RNA level)

          2. No ART for at least previous 3 months

          3. Ready to start or re-start ART (regimen pre-chosen by patient and provider)

        Exclusion Criteria:

          1. Age &lt; 18 years, or &gt;60 years

          2. Pregnancy

          3. Current aspirin use

          4. Presence of known atherosclerotic CVD determined by:

               1. Previous myocardial infarction

               2. Significant coronary atherosclerosis by angiography

               3. Coronary revascularization procedure (coronary stent or surgical bypass)

               4. Previous cerebral vascular accident (stroke)

               5. Ischemic cardiomyopathy

               6. Carotid stenosis (&gt;25% narrowing by carotid ultrasound)

               7. Aortic aneurysm

               8. Symptomatic peripheral vascular disease (claudication)

               9. Surgical revascularization procedure of peripheral vessels

          5. Hospitalization (within prior 2 weeks of study entry)

          6. Concurrent self-limited bacterial infections (does not include chronic viral
             infections)

          7. Clinical or pathologic diagnosis of systemic vasculitis

          8. Active drug or alcohol use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason V Baker, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota; HCMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>October 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2008</study_first_posted>
  <results_first_submitted>January 16, 2012</results_first_submitted>
  <results_first_submitted_qc>March 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2012</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ART and Aspirin</title>
          <description>Start ART immediately and initiate aspirin 325mg po daily</description>
        </group>
        <group group_id="P2">
          <title>ART and Placebo</title>
          <description>Start ART immediately and initiate placebo pill daily</description>
        </group>
        <group group_id="P3">
          <title>Defer and Aspirin</title>
          <description>Defer ART for 1 month and immediately initiate aspirin 325mg po daily</description>
        </group>
        <group group_id="P4">
          <title>Defer and Placebo</title>
          <description>Defer ART for 1 month and immediately initiate placebo pill daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ART and Aspirin</title>
          <description>Start ART immediately and initiate aspirin 325mg po daily</description>
        </group>
        <group group_id="B2">
          <title>ART and Placebo</title>
          <description>Start ART immediately and initiate placebo pill daily</description>
        </group>
        <group group_id="B3">
          <title>Defer and Aspirin</title>
          <description>Defer ART for 1 month and immediately initiate aspirin 325mg po daily</description>
        </group>
        <group group_id="B4">
          <title>Defer and Placebo</title>
          <description>Defer ART for 1 month and immediately initiate placebo pill daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="9.0"/>
                    <measurement group_id="B2" value="38.4" spread="10.6"/>
                    <measurement group_id="B3" value="36.0" spread="9.3"/>
                    <measurement group_id="B4" value="37.5" spread="11.1"/>
                    <measurement group_id="B5" value="37.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Side Effects (Self-report) Number of Participants With Adverse Events</title>
        <description>At each visit participants were asked if they were experience side effects to study medications. They were also asked if any new events or symptoms occurred since the last visit, even if they did not suspect it was related to the study medication</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with adverse events or reporting side effects</population>
        <group_list>
          <group group_id="O1">
            <title>ART and Aspirin</title>
            <description>Start ART immediately and initiate aspirin 325mg po daily</description>
          </group>
          <group group_id="O2">
            <title>ART and Placebo</title>
            <description>Start ART immediately and initiate placebo pill daily</description>
          </group>
          <group group_id="O3">
            <title>Defer and Aspirin</title>
            <description>Defer ART for 1 month and immediately initiate aspirin 325mg po daily</description>
          </group>
          <group group_id="O4">
            <title>Defer and Placebo</title>
            <description>Defer ART for 1 month and immediately initiate placebo pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Side Effects (Self-report) Number of Participants With Adverse Events</title>
          <description>At each visit participants were asked if they were experience side effects to study medications. They were also asked if any new events or symptoms occurred since the last visit, even if they did not suspect it was related to the study medication</description>
          <population>The number of participants with adverse events or reporting side effects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Markers of Inflammation, Endothelial Injury, and Thrombosis</title>
        <time_frame>changes from baseline to 6 months</time_frame>
        <population>Data measurements not obtained, as study terminated early due to poor enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>ART and Aspirin</title>
            <description>Start ART immediately and initiate aspirin 325mg po daily</description>
          </group>
          <group group_id="O2">
            <title>ART and Placebo</title>
            <description>Start ART immediately and initiate placebo pill daily</description>
          </group>
          <group group_id="O3">
            <title>Defer and Aspirin</title>
            <description>Defer ART for 1 month and immediately initiate aspirin 325mg po daily</description>
          </group>
          <group group_id="O4">
            <title>Defer and Placebo</title>
            <description>Defer ART for 1 month and immediately initiate placebo pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Markers of Inflammation, Endothelial Injury, and Thrombosis</title>
          <population>Data measurements not obtained, as study terminated early due to poor enrollment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ART and Aspirin</title>
          <description>Start ART immediately and initiate aspirin 325mg po daily</description>
        </group>
        <group group_id="E2">
          <title>ART and Placebo</title>
          <description>Start ART immediately and initiate placebo pill daily</description>
        </group>
        <group group_id="E3">
          <title>Defer and Aspirin</title>
          <description>Defer ART for 1 month and immediately initiate aspirin 325mg po daily</description>
        </group>
        <group group_id="E4">
          <title>Defer and Placebo</title>
          <description>Defer ART for 1 month and immediately initiate placebo pill daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of subjects analyzed. Study recruitment difficulty due to inclusion of ART deferral component.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jason Baker</name_or_title>
      <organization>Minneapolis Medical Foundation</organization>
      <phone>612-873-2705</phone>
      <email>baker459@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

